130 related articles for article (PubMed ID: 15308927)
1. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine.
Perwien AR; Faries DE; Kratochvil CJ; Sumner CR; Kelsey DK; Allen AJ
J Dev Behav Pediatr; 2004 Aug; 25(4):264-71. PubMed ID: 15308927
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?
Perwien AR; Kratochvil CJ; Faries DE; Vaughan BS; Spencer T; Brown RT
J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):713-24. PubMed ID: 17201615
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents.
Svanborg P; Thernlund G; Gustafsson PA; Hägglöf B; Poole L; Kadesjö B
Eur Child Adolesc Psychiatry; 2009 Apr; 18(4):240-9. PubMed ID: 19156355
[TBL] [Abstract][Full Text] [Related]
4. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
[TBL] [Abstract][Full Text] [Related]
5. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.
Biederman J; Spencer TJ; Newcorn JH; Gao H; Milton DR; Feldman PD; Witte MM
Psychopharmacology (Berl); 2007 Jan; 190(1):31-41. PubMed ID: 17093981
[TBL] [Abstract][Full Text] [Related]
6. [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children].
Gaillez C; Sorbara F; Perrin E
Encephale; 2007 Sep; 33(4 Pt 1):621-8. PubMed ID: 18033153
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.
Michelson D; Faries D; Wernicke J; Kelsey D; Kendrick K; Sallee FR; Spencer T;
Pediatrics; 2001 Nov; 108(5):E83. PubMed ID: 11694667
[TBL] [Abstract][Full Text] [Related]
8. Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder.
Rentz AM; Matza LS; Secnik K; Swensen A; Revicki DA
Qual Life Res; 2005 Apr; 14(3):719-34. PubMed ID: 16022065
[TBL] [Abstract][Full Text] [Related]
9. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.
Wehmeier PM; Schacht A; Dittmann RW; Helsberg K; Schneider-Fresenius C; Lehmann M; Bullinger M; Ravens-Sieberer U
Qual Life Res; 2011 Jun; 20(5):691-702. PubMed ID: 21136299
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
11. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
15. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
[TBL] [Abstract][Full Text] [Related]
16. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
Prasad S; Arellano J; Steer C; Libretto SE
Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.
Christman AK; Fermo JD; Markowitz JS
Pharmacotherapy; 2004 Aug; 24(8):1020-36. PubMed ID: 15338851
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
20. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]